Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2017

View Archived Issues

Heptares gives details on discovery of muscarinic M1 receptor agonist HTL-9936

Phase III results presented for anacetrapib in patients with atherosclerotic vascular disease

U.K. agency backs Themis Bioscience's Chikungunya vaccine

TC BioPharm enters CAR-T agreement with UCL

FDA gives fast track status to NeuroRx's regimen for ASIB in bipolar depression

FDA approves new formulation of Tracleer for pediatric PAH

Novel class of selective PI3Kalpha inhibitors from Genentech tested in vivo

AbbVie submits NDA in U.S. for elagolix

Catalyst Biosciences reports initial data from phase I/II study of CB-2679d in hemophilia B

JDFR supports development of vTv Therapeutics' TTP-399 for type 1 diabetes

Crinetics Pharmaceuticals receives two grants from NIDDK

Palatin Technologies enters bremelanotide licensing agreement with Fosun Pharma

Merck & Co. set to acquire Rigontec

P2Y purinoceptor 6 identified as a target for treating obesity

Morphotek, Johns Hopkins to collaborate on therapies targeting MASAs

Bayer seeks EMA marketing approval for BAY-94-9027 for hemophilia A

Verastem reports phase III topline data on duvelisib in CLL/SLL, expands program into PTCL

BMS-986144 presented as a promising anti-HCV treatment

CSIR patents silicon-based cyclic antiparasitics

Zealand Pharma and Orbit Discovery form multi-target research collaboration

Shanghai Institute Materia Medica discovers new AMP-activated protein kinase activators

Novartis initiates phase III trial of ABL-001 in chronic phase CML

Novel phosphodiesterase PDE4B/A/C inhibitors identified at Pfizer

EMA grants orphan drug designation to Vivus' tacrolimus for PAH

Daiichi Sankyo and Sanford Burnham Prebys begin clinical trial of DS-1211

VIB, Universiteit Ghent and Orionis Biosciences divulge PD-L1-targeting fusion proteins

Lilly presents novel RANKL-targeting fusion proteins

FDA places partial clinical hold on Opdivo combination trials in multiple myeloma

Evotec and Abivax partner to discover and develop novel antiviral agents